Suppression of antigen-specific antibody responses in mice exposed to perfluorooctanoic acid: Role of PPARα and T- and B-cell targeting

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Immunotoxicology

• Publication date

  2016-01-02

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.3109/1547691X.2014.996682PMID 25594567
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate.

  2014influential reference
• Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood

  2013cited by this paper
• In vitro characterization of the immunotoxic potential of several perfluorinated compounds (PFCs).

  2012cited by this paper
• Serum vaccine antibody concentrations in children exposed to perfluorinated compounds.

  2012cited by this paper
• In vitro evaluation of the immunotoxic potential of perfluorinated compounds (PFCs).

  2011cited by this paper
• Microgram-order ammonium perfluorooctanoate may activate mouse peroxisome proliferator-activated receptor alpha, but not human PPARalpha.

  2009cited by this paper
• Perfluorooctanoic Acid–Induced Immunomodulation in Adult C57BL/6J or C57BL/6N Female Mice

  2008cited by this paper
• Evaluation of the immune system in rats and mice administered linear ammonium perfluorooctanoate.

  2008influential reference
• Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate.

  2008influential reference
• Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate.

  2007cited by this paper
• The PPAR resource page.

  2007cited by this paper
• Immunotoxicity: the risk is real.

  2007cited by this paper
• Activation of Mouse and Human Peroxisome Proliferator-Activated Receptors ( , / , ) by Perfluorooctanoic Acid and Perfluorooctane Sulfonate

  2006cited by this paper
• B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae.

  2005cited by this paper
• Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid.

  2002influential reference
• Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice.

  2002influential reference
• Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluoroctanoic acid in mice.

  2001cited by this paper
• Effects of peroxisome proliferators on the thymus and spleen of mice

  2000cited by this paper
• B-1 and B-2 Cell–Derived Immunoglobulin M Antibodies Are Nonredundant Components of the Protective Response to Influenza Virus Infection

  2000cited by this paper
• Use of immunotoxicity data in health risk assessments: uncertainties and research to improve the process.

  1998cited by this paper
• Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests.

  1993cited by this paper
• Risk assessment in immunotoxicology. I. Sensitivity and predictability of immune tests.

  1992cited by this paper
• Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS)

  year unknowncited by this paper

• PFOS and PFOA exposure induces liver injury and sex-dependent immune effects in C57BL/6 mice

  2026cites this paper
• The Association Between Serum Perfluorooctanoic Acid (PFOA) Above the Intervention Threshold Level and Vaccine Antibody Concentrations in an Environmentally Exposed Population

  2026cites this paper
• An overview of the impact of PFAS on animals, humans, and the environment using a One Health approach

  2026cites this paper
• Associations of Serum PFAS with COVID-19 Antibody Levels among Fully Vaccinated Adults.

  2026cites this paper
• Impact of per- and polyfluoroalkyl substances (PFAS) in wild plants, soil and water in two Austrian national parks.

  2025cites this paper
• Immunotoxicity of Four Per- and Polyfluoroalkyl Substances Following 28-Day Oral Repeat Dosing in Rats Assessed by the Anti-Sheep Red Blood Cell IgM Response

  2025cites this paper
• Range of the perfluorooctanoate (PFOA) safe dose for human health: an international collaboration

  2025cites this paper
• Method development and validation for analysis of 74 per- and polyfluoroalkyl substances (PFAS) in food of animal origin using QuEChERSER method and LC-MS/MS.

  2025cites this paper
• A comparative toxicological and epidemiological evaluation of dioxins and PFAS chemicals

  2025cites this paper
• Developmental exposure to a PFAS mixture impairs the anamnestic response to influenza A virus infection in mice

  2025cites this paper
• Perfluorooctanoic Acid Disrupts Splenic Immunity and Antiviral Responses in the LCMV Model: Insights from Single-Cell Transcriptomics.

  2025cites this paper
• Perfluorooctane sulfonate (PFOS) and its selected analogs induce various cell death types in peripheral blood mononuclear cells.

  2024cites this paper
• Mode of Action Criteria for Selection of the Critical Effect and Safe Dose Range for PFOA by the Alliance for Risk Assessment.

  2024cites this paper
• S03-04 Effects of PFAS exposure on B cell functions

  2024cites this paper
• Binary and quaternary mixtures of perfluoroalkyl substances (PFAS) differentially affect the immune response to influenza A virus infection

  2024influential citation
• Immune cell profiles associated with human exposure to perfluorinated compounds (PFAS) suggest changes in natural killer, T helper, and T cytotoxic cell subpopulations

  2024cites this paper
• Determination of in vitro immunotoxic potencies of a series of perfluoralkylsubstances (PFASs) in human Namalwa B lymphocyte and human Jurkat T lymphocyte cells

  2024cites this paper
• Systemic and immunotoxicity induced by topical application of perfluorohexane sulfonic acid (PFHxS) in a murine model.

  2024cites this paper
• Occurrence of COVID-19 and serum per- and polyfluoroalkyl substances: A case-control study among workers with a wide range of exposures

  2024cites this paper
• Internal relative potency factors based on immunotoxicity for the risk assessment of mixtures of per- and polyfluoroalkyl substances (PFAS) in human biomonitoring.

  2023cites this paper
• Prenatal Exposure to Poly- and Perfluoroalkyl Substances (2009–2014) and Vaccine Antibody Titers of Measles, Mumps, Rubella, and Varicella in Children Four to Eight Years Old from the Healthy Start Cohort

  2023cites this paper
• Range of the perfluorooctanoate (PFOA) safe dose for human health: An international collaboration.

  2023influential citation
• Perfluorooctanoic Acid Promotes Recruitment and Exocytosis of Rodlet Cells in the Renal Hematopoietic Tissue of Common Carp

  2023cites this paper
• C57BL/6J mice exposed to perfluorooctanoic acid demonstrate altered immune responses and increased seizures after Theiler’s murine encephalomyelitis virus infection

  2023cites this paper
• Immune response to COVID-19 vaccination in a population with a history of elevated exposure to per- and polyfluoroalkyl substances (PFAS) through drinking water

  2023cites this paper
• Prenatal exposures to per- and polyfluoroalkyl substances and epigenetic aging in umbilical cord blood: The healthy start study.

  2023cites this paper
• Quantifying the impact of PFOA exposure on B-cell development and antibody production

  2023influential citation
• Weight of evidence evaluation for chemical-induced immunotoxicity for PFOA and PFOS: findings from an independent panel of experts

  2023cites this paper
• Current per- and polyfluoroalkyl substance (PFAS) research points to a growing threat in animals.

  2023cites this paper
• Consideration of pathways for immunotoxicity of per- and polyfluoroalkyl substances (PFAS)

  2023cites this paper
• Legacy and emerging per- and polyfluoroalkyl substances suppress the neutrophil respiratory burst

  2023cites this paper
• Systematic review and meta-analysis of epidemiologic data on vaccine response in relation to exposure to five principal perfluoroalkyl substances.

  2023cites this paper
• Evaluation of Neural Regulation and Microglial Responses to Brain Injury in Larval Zebrafish Exposed to Perfluorooctane Sulfonate

  2023cites this paper
• Next-Generation Pfas 6:2 Fluorotelomer Sulfonate Reduces Plaque Formation in Exposed White-Footed Mice.

  2023cites this paper
• Association of increased risk of cardiovascular diseases with higher levels of perfluoroalkylated substances in the serum of adults

  2022cites this paper
• PFAS Experts Symposium 2: PFAS Toxicology and Risk Assessment in 2021 and risk assessment in 2021—Contemporary issues in human and ecological risk assessment of PFAS

  2022cites this paper
• Method development and evaluation for the determination of perfluoroalkyl and polyfluoroalkyl substances in multiple food matrices

  2022cites this paper
• The toxicity of perfluorodecanoic acid is mainly manifested as a deflected immune function

  2022cites this paper
• Gestational Perfluoroalkyl Substance Exposure and DNA Methylation at Birth and 12 Years of Age: A Longitudinal Epigenome-Wide Association Study

  2022cites this paper
• Perfluorooctanesulfonate (PFOS) and perfluorooctanoic acid (PFOA) modify in vitro mitogen- and antigen-induced human peripheral blood mononuclear cell (PBMC) responses

  2022cites this paper
• Pulmonary exposure of mice to ammonium perfluoro(2-methyl-3-oxahexanoate) (GenX) suppresses the innate immune response to carbon black nanoparticles and stimulates lung cell proliferation

  2022influential citation
• An unexpected synergistic toxicity caused by competitive bioconcentration of perfluoroalkyl acid mixtures to Daphnia magna: Further promoted by elevated temperature.

  2022cites this paper
• Perfluoroalkyl substances (PFASs) decrease the expression of recombination-activating genes (RAG1 and RAG2) in human B lymphoma Namalwa cells

  2022cites this paper
• Toxicity assessment of hexafluoropropylene oxide-dimer acid on morphology, heart physiology, and gene expression during zebrafish (Danio rerio) development

  2022cites this paper
• A systematic evidence map of chronic inflammation and immunosuppression related to per- and polyfluoroalkyl substance (PFAS) exposure

  2022cites this paper
• Per�uorooctanoic acid exposure and its neurodegenerative consequences

  2022cites this paper
• Per- and polyfluoroalkyl mixtures toxicity assessment “Proof-of-Concept” illustration for the hazard index approach

  2021cites this paper
• Association between maternal serum concentration of perfluoroalkyl substances (PFASs) at delivery and acute infectious diseases in infancy.

  2021cites this paper
• Immunotoxicity mechanisms of perfluorinated compounds PFOA and PFOS.

  2021cites this paper
• Association of maternal exposure to perfluoroalkyl and polyfluroalkyl substances with infant growth from birth to 12 months: A prospective cohort study.

  2021cites this paper
• Plasma concentrations of perfluoroalkyl substances and risk of inflammatory bowel diseases in women: A nested case control analysis in the Nurses' Health Study cohorts.

  2021cites this paper
• Suppression of Th2 cytokines as a potential mechanism for reduced antibody response following PFOA exposure in female B6C3F1 mice.

  2021cites this paper
• Serum vaccine antibody concentrations in adults exposed to per- and polyfluoroalkyl substances: A birth cohort in the Faroe Islands

  2021cites this paper
• Immunotoxicity of Per- and Polyfluoroalkyl Substances: Insights into Short-Chain PFAS Exposure

  2021influential citation
• News Feature: How “forever chemicals” might impair the immune system

  2021cites this paper
• Immunometabolism-modulation and immunotoxicity evaluation of perfluorooctanoic acid in macrophage.

  2021cites this paper
• Exposure, health effects, sensing, and remediation of the emerging PFAS contaminants - Scientific challenges and potential research directions.

  2021cites this paper
• Critical evaluation of ToxCast-Reactome predicted toxicity pathway correspondence of the human liver HepG2 activity profile with observed PFOA and PFOS hazards

  2021cites this paper
• Metabolomic analysis reveals metabolic alterations of human peripheral blood lymphocytes by perfluorooctanoic acid.

  2020cites this paper
• Toxicology and carcinogenesis studies of perfluorooctanoic acid administered in feed to Sprague Dawley (Hsd:Sprague Dawley SD) rats.

  2020cites this paper
• Prenatal Exposure to Per- and Polyfluoroalkyl Substances, Umbilical Cord Blood DNA Methylation, and Cardio-Metabolic Indicators in Newborns: The Healthy Start Study

  2020cites this paper
• Suggestions for Improving the Characterization of Risk from Exposures to Per and Polyfluorinated Alkyl Substances

  2020cites this paper
• Risk to human health related to the presence of perfluoroalkyl substances in food

  2020cites this paper
• Immunotoxicity of an Electrochemically Fluorinated Aqueous Film-Forming Foam.

  2020cites this paper
• Exposure to perfluorooctanoic acid (PFOA) decreases neutrophil migration response to injury in zebrafish embryos

  2020cites this paper
• Are Persistent Organic Pollutants Linked to Lipid Abnormalities, Atherosclerosis and Cardiovascular Disease? A Review

  2020cites this paper
• An international validation study of the IL-2 Luc assay for evaluating the potential immunotoxic effects of chemicals on T cells and a proposal for reference data for immunotoxic chemicals

  2020cites this paper
• Immunotoxicity and allergenic potential induced by topical application of perfluorooctanoic acid (PFOA) in a murine model.

  2020cites this paper
• Unravelling the mechanisms of PFOS toxicity by combining morphological and transcriptomic analyses in zebrafish embryos.

  2019cites this paper
• Microbial responses to perfluoroalkyl substances and perfluorooctanesulfonate (PFOS) desulfurization in the Antarctic marine environment.

  2019cites this paper
• Immunotoxic and hepatotoxic effects of perfluoro-n-decanoic acid (PFDA) on female Harlan Sprague–Dawley rats and B6C3F1/N mice when administered by oral gavage for 28 days

  2018cites this paper
• Changes in plasma levels of perfluoroalkyl substances (PFASs) are related to increase in carotid intima-media thickness over 10 years – a longitudinal study

  2018cites this paper
• GenX Inhibits P-glycoprotein and Breast Cancer Resistance Protein Transport Activity and Expression at the Blood-Brain Barrier in Sprague-Dawley Rats

  2018cites this paper
• Beta-2 Adrenergic and Glucocorticoid Receptor Agonists Modulate Ozone-Induced Pulmonary Protein Leakage and Inflammation in Healthy and Adrenalectomized Rats

  2018cites this paper
• Developmental Exposures to Perfluoroalkyl Substances (PFASs): An Update of Associated Health Outcomes

  2018cites this paper
• Circulating levels of perfluoroalkyl substances (PFASs) and carotid artery atherosclerosis

  2017cites this paper
• Evaluation of the Immunomodulatory Effects of 2,3,3,3-Tetrafluoro-2-(Heptafluoropropoxy)-Propanoate in C57BL/6 Mice

  2017influential citation
• Perfluoroalkyl acids-induced liver steatosis: Effects on genes controlling lipid homeostasis.

  2017cites this paper
• Comments Regarding the Systematic Review of Immunotoxicity Associated with Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS)

  2016cites this paper
• Health Effects Support Document for Perfluorooctane Sulfonate (PFOS)

  2016cites this paper
• Per- and polyfluorinated substances (PFASs): Environmental challenges

  2015cites this paper